Tirzepatide
Tirzepatide (Mounjaro) Over the past few years, tirzepatide has emerged as one of the most promising treatments for obesity and type 2 diabetes. Marketed under brand names such as Mounjaro and Zepbound , this dual GIP and GLP-1 receptor agonist has not only demonstrated impressive clinical results but is also reshaping the future of weight management. Here’s a look at the latest research, benefits, and safety considerations surrounding tirzepatide as of April 2025. 🧬 What is Tirzepatide? Tirzepatide is a once-weekly injectable medication that mimics the effects of two key gut hormones: Glucose-dependent insulinotropic polypeptide (GIP) Glucagon-like peptide-1 (GLP-1) This dual action stimulates insulin production, slows gastric emptying, and suppresses appetite — resulting in significant weight loss and improved blood sugar control . ✅ Proven Benefits 1. Sustained, Significant Weight Loss The SURMOUNT-1 trial , a pivotal Phase 3 study, showed that indiv...